Cencora (COR) Expected to Announce Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $4.04 per share and revenue of $86.1184 billion for the quarter. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same period in the previous year, the company posted $3.34 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts expect Cencora to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Cencora Stock Up 1.3%

COR stock opened at $363.73 on Tuesday. The company has a market cap of $70.56 billion, a price-to-earnings ratio of 45.75, a price-to-earnings-growth ratio of 1.71 and a beta of 0.68. The company has a fifty day moving average price of $347.46 and a 200 day moving average price of $324.75. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. Cencora has a 12 month low of $237.71 and a 12 month high of $377.54.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 20,316 shares of company stock worth $7,151,265. Company insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

Institutional investors and hedge funds have recently made changes to their positions in the stock. Evergreen Capital Management LLC lifted its stake in shares of Cencora by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock valued at $370,000 after purchasing an additional 45 shares during the period. Prelude Capital Management LLC increased its holdings in Cencora by 2.7% in the third quarter. Prelude Capital Management LLC now owns 2,208 shares of the company’s stock valued at $690,000 after buying an additional 59 shares in the last quarter. Ancora Advisors LLC lifted its position in shares of Cencora by 1.5% during the 3rd quarter. Ancora Advisors LLC now owns 4,261 shares of the company’s stock valued at $1,332,000 after acquiring an additional 64 shares during the period. Modern Wealth Management LLC boosted its stake in shares of Cencora by 7.6% during the 2nd quarter. Modern Wealth Management LLC now owns 1,118 shares of the company’s stock worth $335,000 after acquiring an additional 79 shares in the last quarter. Finally, Keel Point LLC boosted its stake in shares of Cencora by 5.3% during the 2nd quarter. Keel Point LLC now owns 1,632 shares of the company’s stock worth $489,000 after acquiring an additional 82 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on COR. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Mizuho boosted their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Robert W. Baird set a $415.00 target price on Cencora in a research note on Tuesday, January 13th. Finally, UBS Group boosted their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.